Company Filing History:
Years Active: 2018
Title: Ida Kjaer: Innovator in Cancer Treatment
Introduction
Ida Kjaer is a prominent inventor based in Copenhagen, Denmark. She has made significant contributions to the field of cancer treatment through her innovative research and development of humanized antibodies. Her work focuses on targeting the EGFR family receptors, which play a crucial role in cancer progression.
Latest Patents
Ida Kjaer holds a patent for her invention titled "Methods for treating cancer by administering humanized pan-HER antibody compositions." This invention relates to humanized recombinant antibodies that target the EGFR family receptors, including EGFR, HER2, and HER3. The patent describes compositions that comprise at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody, and at least one humanized anti-HER3 antibody. The use of these antibody compositions is aimed at treating various types of cancer, including pancreatic cancer and cancer that has developed resistance to previous therapies.
Career Highlights
Ida Kjaer is associated with Symphogen A/S, a company known for its focus on developing antibody-based therapies. Her work at Symphogen has been instrumental in advancing the understanding and treatment of cancer through innovative antibody technologies.
Collaborations
Ida collaborates with various professionals in her field, including her coworker Johan Lantto. Their combined expertise contributes to the ongoing research and development efforts at Symphogen.
Conclusion
Ida Kjaer is a trailblazer in the field of cancer treatment, with her innovative patent and work at Symphogen A/S. Her contributions are paving the way for new therapeutic approaches to combat cancer effectively.